Active Multiple Myeloma Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Multiple Myeloma Clinical Trial?

• Find Trials That Fit — Browse recruiting Multiple Myeloma trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Multiple Myeloma type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Multiple Myeloma Clinical Trial FAQ

What are BCMA-targeted therapies, and are there myeloma trials for them?

BCMA (B-cell maturation antigen) is a protein highly expressed on myeloma cells. FDA-approved BCMA-targeted therapies include CAR-T products (idecabtagene vicleucel, ciltacabtagene autoleucel) and bispecific antibodies (teclistamab, elranatamab). Clinical trials are testing next-generation BCMA CAR-T constructs, dual-target approaches (BCMA + other antigens), and BCMA therapies in earlier lines of treatment.

Can newly diagnosed myeloma patients join clinical trials?

Yes. There are active trials for newly diagnosed multiple myeloma testing whether adding a fourth drug to the standard triplet backbone improves outcomes, and whether maintenance therapy after transplant or beyond can extend remission. Transplant-eligible and transplant-ineligible patients are enrolled in separate studies.

What does "refractory to lenalidomide and daratumumab" mean for trial eligibility?

Lenalidomide (Revlimid) and daratumumab (Darzalex) are among the most widely used myeloma drugs. Being refractory means your cancer stopped responding to or progressed while on these agents. Many trials for relapsed/refractory myeloma specifically require prior exposure to (and refractoriness to) these drugs, making you eligible for newer agents like bispecific antibodies and novel CAR-T therapies.

Do I need to have had a stem cell transplant to join most myeloma trials?

No. Both transplant-eligible and transplant-ineligible patients are enrolled in trials across all lines of treatment. Some trials require or exclude prior transplant — this is specified in the eligibility criteria. Trialify's questionnaire will ask about your transplant history so you only see relevant trials.

How do I track whether a myeloma trial has an open slot near me?

Trial enrollment can fill quickly for popular studies. Trialify shows you which sites are currently recruiting and how far they are from your ZIP code. You can save a trial to your dashboard and receive email notifications if the trial status changes, so you're alerted if a site near you opens enrollment.

Explore Other Cancer Trial Guides

• Lymphoma — Lymphoma trials are studying CAR-T cell therapies, bispecific antibodies, and targeted agents for both Hodgkin and non-Hodgkin subtypes — including diffuse large B-cell, follicular, and mantle cell lymphoma.
• Leukemia — Leukemia trials are testing targeted inhibitors, CAR-T therapies, and novel transplant strategies for AML, ALL, CLL, and CML. New treatment options are emerging rapidly across all leukemia types.
• Breast Cancer — Breast cancer trials are testing innovative therapies for all subtypes — HER2+, triple-negative (TNBC), and hormone receptor-positive. New options are opening every month at cancer centers across the country.
• Prostate Cancer — Prostate cancer trials are exploring next-generation hormone therapies, PARP inhibitors, radiopharmaceuticals, and novel immunotherapy combinations — including options for castration-resistant disease.